Go Pro
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free ENLV Stock Alerts

Enlivex Therapeutics (ENLV) Financials

Enlivex Therapeutics logo
$6.94 -0.27 (-3.73%)
As of 01:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Enlivex Therapeutics

Annual Income Statements for Enlivex Therapeutics

This table shows Enlivex Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -15 1,236
Consolidated Net Income / (Loss)		 -15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -15 1,236
Net Income / (Loss) Continuing Operations		 -15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -15 1,236
Total Pre-Tax Income 		-15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -15 1,618
Total Operating Income		 -15 -16 -2.17 -5.30 -8.62 -9.79 -19 -26 -29 -16 -15
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 - 0.00 - - - - - - - - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 15 16 2.17 5.30 8.62 9.79 19 26 29 16 15
Selling, General & Admin Expense		 6.95 5.90 0.48 1.29 3.02 3.70 6.41 7.10 10 5.27 5.83
Research & Development Expense		 7.69 8.88 1.69 4.01 5.60 6.09 13 19 19 11 9.20
Total Other Income / (Expense), net		 0.14 0.06 -0.33 1.06 -0.77 -2.04 4.82 -5.26 0.33 0.87 1,633
Other Income / (Expense), net		 - 0.06 -0.33 1.06 -0.77 -2.04 4.82 -5.26 - - 1,633
Income Tax Expense		 0.02 0.22 - - - - - - 0.00 0.00 383
Basic Earnings per Share		 ($5.40) ($40.13) ($0.94) ($1.40) - ($0.90) ($0.81) ($1.69) ($1.56) ($0.73) $27.04
Weighted Average Basic Shares Outstanding		 2.85M 399.22K 3.43M 3.51M 8.65M 13.17M 17.86M 18.39M 18.57M 20.51M 45.70M
Diluted Earnings per Share		 ($5.40) ($40.13) ($0.94) ($1.40) - - - ($1.69) ($1.56) ($0.73) $25.48
Weighted Average Diluted Shares Outstanding		 2.85M 399.22K 3.43M 3.51M 8.65M 13.17M 18.33M 18.39M 18.57M 20.51M 48.50M
Weighted Average Basic & Diluted Shares Outstanding		 2.85M 399.22K 3.43M 3.51M 8.65M 13.17M 18.33M 18.42M 18.60M 23.65M 237.38M

Quarterly Income Statements for Enlivex Therapeutics

No quarterly income statements for Enlivex Therapeutics are available.

Annual Cash Flow Statements for Enlivex Therapeutics

This table details how cash moves in and out of Enlivex Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.30 -0.42 5.62 1.53 -5.09 1.10 5.03 39 -49 2.51 -1.36
Net Cash From Operating Activities		 -13 -15 -2.30 -3.16 -7.04 -11 -18 -24 -24 -13 -10
Net Cash From Continuing Operating Activities		 -13 -15 -2.30 -3.16 -7.04 -11 -18 -24 -24 -13 -10
Net Income / (Loss) Continuing Operations		 -15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -15 1,236
Consolidated Net Income / (Loss)		 -15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -15 1,236
Depreciation Expense		 0.02 0.04 0.08 0.12 0.21 0.29 0.55 0.78 0.84 0.55 0.33
Non-Cash Adjustments To Reconcile Net Income		 2.61 1.14 0.13 0.88 1.10 0.84 -2.26 5.53 6.53 2.68 -1,630
Changes in Operating Assets and Liabilities, net		 -0.51 -0.64 -0.02 0.08 1.04 -0.31 -1.36 0.80 -1.82 -1.22 383
Net Cash From Investing Activities		 9.95 8.98 -0.13 -0.50 -6.36 -21 -38 63 -26 9.06 -1.32
Net Cash From Continuing Investing Activities		 9.95 8.98 -0.13 -0.50 -6.36 -21 -38 63 -26 9.06 -1.32
Purchase of Property, Plant & Equipment		 -0.05 -0.02 -0.13 -0.46 -0.19 -1.02 -1.63 -8.12 -0.24 -0.10 -0.07
Purchase of Investments		 - - 0.00 -0.04 -7.71 -20 -104 -1.91 -26 -32 -24
Sale of Property, Plant & Equipment		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.13 2.29 1.38
Sale and/or Maturity of Investments		 - - - - 0.00 0.00 48 63 0.30 39 41
Other Investing Activities, net		 10 9.00 - - - - 20 10 0.00 0.00 -20
Net Cash From Financing Activities		 0.00 6.09 8.06 5.19 8.31 33 61 0.15 0.36 6.45 10
Net Cash From Continuing Financing Activities		 0.00 6.09 8.06 5.19 8.31 33 61 0.15 0.36 6.45 10
Issuance of Common Equity		 0.00 6.09 - - - - 53 0.00 0.36 6.45 10
Other Financing Activities, net		 0.00 0.00 0.00 0.00 0.60 8.62 7.81 0.15 0.00 0.00 0.00
Cash Interest Paid		 - - - - - - 0.12 0.84 1.57 1.48 1.14
Cash Income Taxes Paid		 0.00 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Enlivex Therapeutics

No quarterly cash flow statements for Enlivex Therapeutics are available.

Annual Balance Sheets for Enlivex Therapeutics

This table presents Enlivex Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 21 11 3.62 11 18 40 95 68 37 28 2,327
Total Current Assets		 20 11 3.62 10 16 38 86 52 34 26 1,743
Cash & Equivalents		 7.29 6.87 3.53 9.74 3.95 5.67 11 50 0.81 3.30 1.89
Short-Term Investments		 - - - - - 0.00 63 0.30 27 20 3.86
Prepaid Expenses		 1.06 0.66 - 0.29 0.91 1.24 2.31 2.09 1.34 2.30 4.36
Other Current Nonoperating Assets		 - - - - - - - 0.00 5.11 0.20 0.00
Plant, Property, & Equipment, net		 0.09 0.07 0.00 0.69 0.65 1.48 2.53 9.88 1.54 0.63 0.36
Total Noncurrent Assets		 0.03 0.02 0.00 0.07 0.49 0.76 6.17 5.44 1.53 1.07 2,317
Other Noncurrent Operating Assets		 0.03 0.02 - 0.07 0.49 0.76 6.17 5.44 1.53 1.07 2,317
Total Liabilities & Shareholders' Equity		 21 11 3.62 11 18 40 95 68 37 28 2,327
Total Liabilities		 2.58 1.93 0.46 1.33 6.28 4.87 10 11 6.75 4.10 392
Total Current Liabilities		 2.51 1.93 0.46 1.13 5.98 4.37 4.72 6.61 6.06 3.80 9.02
Accounts Payable		 2.51 1.93 0.46 1.13 2.58 3.20 4.72 1.95 0.83 0.81 3.81
Accrued Expenses		 - - - - - - - 4.66 4.00 2.85 5.21
Other Current Nonoperating Liabilities		 - - - - - - - 0.00 1.23 0.14 0.00
Total Noncurrent Liabilities		 0.07 0.00 0.00 0.20 0.30 0.50 5.39 4.19 0.69 0.30 383
Capital Lease Obligations		 - - - - - - - - - - 0.38
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 383
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 18 8.70 3.16 9.71 11 35 85 57 30 24 1,935
Total Preferred & Common Equity		 18 8.70 3.16 9.71 11 35 85 57 30 24 1,935
Total Common Equity		 18 8.70 3.16 9.18 11 35 85 57 30 24 1,935
Common Stock		 42 49 49 28 38 72 136 139 141 150 825
Retained Earnings		 -24 -40 -46 -16 -26 -37 -52 -83 -112 -127 1,108
Accumulated Other Comprehensive Income / (Loss)		 - - - -2.25 -1.30 0.98 1.10 1.10 1.10 1.10 1.10

Quarterly Balance Sheets for Enlivex Therapeutics

No quarterly balance sheets for Enlivex Therapeutics are available.

Annual Metrics And Ratios for Enlivex Therapeutics

This table displays calculated financial ratios and metrics derived from Enlivex Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 14,230,480.00 16,391,770.00 3,342,393.00 840,443.00 10,334,126.00 14,587,934.00 18,331,507.00 18,421,852.00 18,598,555.00 18,598,555.00 18,598,555.00
DEI Adjusted Shares Outstanding		 355,762.00 409,794.00 417,799.00 105,055.00 10,334,126.00 14,587,934.00 18,331,507.00 18,421,852.00 18,598,555.00 18,598,555.00 18,598,555.00
DEI Earnings Per Adjusted Shares Outstanding		 -43.19 -39.10 -5.99 -40.38 -0.91 -0.81 -0.79 -1.69 -1.56 -0.81 66.43
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -11 -11 -1.52 -3.71 -6.03 -6.85 -14 -18 -21 -11 -11
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -31.77% -68.40% -47.15% -0.59%
Earnings before Interest and Taxes (EBIT)		 -15 -16 -2.50 -4.24 -9.38 -12 -14 -31 -29 -16 1,618
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -16 -2.42 -4.12 -9.18 -12 -14 -30 -29 -15 1,619
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.39 -2.29 0.67 -4.04 -14 -30 0.51 -8.35 -13 -12 -1,941
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 1.83 -0.36 -0.03 7.53 30 16 6.60 -1.11 0.04 1,930
Increase / (Decrease) in Invested Capital		 -9.45 -8.82 -2.19 0.33 7.56 23 -14 -9.71 -7.71 1.15 1,930
Book Value per Share		 $1.26 $0.61 $0.19 $2.75 $26.87 $3.43 $5.83 $3.10 $1.63 $1.27 $42.34
Tangible Book Value per Share		 $1.26 $0.61 $0.19 $2.75 $26.87 $3.43 $5.83 $3.10 $1.63 $1.27 $42.34
Total Capital		 18 8.70 3.16 9.71 12 36 90 57 30 24 1,935
Total Debt		 0.00 0.00 0.00 0.00 0.30 0.50 5.39 0.00 0.00 0.00 0.38
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.30 0.50 5.39 0.00 0.00 0.00 0.38
Net Debt		 -7.29 -6.87 -3.53 -9.74 -3.75 -5.17 -69 -50 -27 -23 -5.37
Capital Expenditures (CapEx)		 0.05 0.02 0.13 0.46 0.19 1.02 1.63 8.12 0.10 -2.19 -1.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 1.74 -0.36 -0.59 6.39 28 7.60 -4.52 0.38 -1.30 1,728
Debt-free Net Working Capital (DFNWC)		 18 8.61 3.16 9.15 10 34 82 46 28 22 1,734
Net Working Capital (NWC)		 18 8.61 3.16 9.15 10 34 82 46 28 22 1,734
Net Nonoperating Expense (NNE)		 4.53 4.92 0.98 0.53 3.35 4.97 0.97 13 8.49 3.89 -1,247
Net Nonoperating Obligations (NNO)		 -7.29 -6.87 -3.53 -9.74 -3.75 -5.17 -69 -50 -31 -24 -5.37
Total Depreciation and Amortization (D&A)		 0.02 0.04 0.08 0.12 0.21 0.29 0.55 0.78 0.84 0.55 0.33
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $43.20 ($40.40) $0.00 $0.00 ($1.11) ($0.90) $0.00 ($1.69) ($1.56) ($0.73) $27.04
Adjusted Weighted Average Basic Shares Outstanding		 355.76K 409.79K 417.80K 0.00 10.33M 14.59M 18.33M 18.42M 18.57M 20.51M 45.70M
Adjusted Diluted Earnings per Share		 $43.20 ($40.40) $0.00 $0.00 ($1.11) ($0.90) $0.00 $0.00 $0.00 ($0.73) $25.48
Adjusted Weighted Average Diluted Shares Outstanding		 355.76K 409.79K 417.80K 0.00 10.33M 14.59M 18.33M 18.42M 18.60M 20.51M 48.50M
Adjusted Basic & Diluted Earnings per Share		 $43.20 ($40.40) $0.00 $0.00 ($1.11) ($0.90) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 355.76K 397.66K 414.20K 0.00 8.65M 13.17M 18.33M 18.42M 18.60M 23.65M 237.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -11 -1.52 -3.71 -6.03 -6.85 -14 -18 -21 -11 -11
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Enlivex Therapeutics

No quarterly metrics and ratios for Enlivex Therapeutics are available.


Financials Breakdown Chart

Enlivex Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Enlivex Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Enlivex Therapeutics' net income appears to be on an upward trend, with a most recent value of $1.24 billion in 2025, falling from -$15.37 million in 2015. The previous period was -$15.01 million in 2024. See where experts think Enlivex Therapeutics is headed by visiting Enlivex Therapeutics' forecast page.

Enlivex Therapeutics' total operating income in 2025 was -$15.03 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $15.03 million

Over the last 10 years, Enlivex Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Enlivex Therapeutics' total liabilities were at $392.05 million at the end of 2025, a 9,466.9% increase from 2024, and a 15,072.2% increase since 2015.

In the past 10 years, Enlivex Therapeutics' cash and equivalents has ranged from $813 thousand in 2023 to $49.95 million in 2022, and is currently $1.89 million as of their latest financial filing in 2025.

Over the last 10 years, Enlivex Therapeutics' book value per share changed from 1.26 in 2015 to 42.34 in 2025, a change of 3,260.3%.


Related Companies

Financial statements for NASDAQ:ENLV last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel